Related references
Note: Only part of the references are listed.Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer
Wassim Kassouf et al.
JOURNAL OF UROLOGY (2006)
Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation
G Nicolle et al.
CLINICAL CANCER RESEARCH (2006)
Patterns of invasion and histological growth as prognostic indicators in urothelial carcinoma of the upper urinary tract
C Langner et al.
VIRCHOWS ARCHIV (2006)
Frequency and clinicopathologic correlates of Erb131, Erb132, and Erb133 immunoreactivity in urothelial tumors of upper urinary tract
YS Tsai et al.
UROLOGY (2005)
erbB receptor expression patterns in human bladder cancer
PH Rajjayabun et al.
UROLOGY (2005)
Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods?
AP Dei Tos et al.
EUROPEAN JOURNAL OF CANCER (2005)
Expression of the epidermal growth factor receptor family in normal and malignant urothelium
R Rotterud et al.
BJU INTERNATIONAL (2005)
Clinical applications for targeted therapy in bladder cancer
L Adam et al.
UROLOGIC CLINICS OF NORTH AMERICA (2005)
Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines
SB Maddineni et al.
BRITISH JOURNAL OF CANCER (2005)
HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: Systematic analysis applying tissue microarray technique
C Langner et al.
UROLOGY (2005)
Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
JE Nutt et al.
BRITISH JOURNAL OF CANCER (2004)
Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer
LA McHugh et al.
UROLOGY (2004)
Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications
Z Popov et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2004)
Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer
JL Dominguez-Escrig et al.
CLINICAL CANCER RESEARCH (2004)
Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?
C Langner et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Transitional cell carcinoma of the ureter and renal pelvis
Z Kirkali et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2003)
Progress in the chemotherapy of metastatic cancer of the urinary tract
D Raghavan
CANCER (2003)
FDA drug approval summary: Gefitinib (ZD1839) (Iressa (R)) tablets
MH Cohen et al.
ONCOLOGIST (2003)
Share Paper
